OBLN Obalon Therapeutics

Obalon Announces Upcoming Conference Presentations

Obalon Announces Upcoming Conference Presentations

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: ), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Kelly Huang, President and Chief Operating Officer, and Bill Plovanic, Chief Financial Officer of Obalon, will participate in the following upcoming investor conferences:

Stifel Healthcare Conference                                                                                

Wednesday, November 14, 2018, Presentation at 1:15pm ET

Lotte New York Palace Hotel, New York City

Webcast Available at:

Canaccord Genuity Medical Technologies & Diagnostics Forum

Thursday, November 15, 2018, Presentation at 1:30pm ET                                                             

Westin Grand Central Hotel, New York City         

Webcast Available at:

Live audio webcasts of the presentation can be accessed through the link above. Replays of the webcasts will be available for 90 days following each presentation.

About Obalon Therapeutics, Inc.

Obalon Therapeutics, Inc. (NASDAQ: ) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit .

For Obalon Therapeutics, Inc.

Investor Contact:

William Plovanic

Chief Financial Officer

Obalon Therapeutics, Inc.

Office:

Media:

Megan Driscoll

EvolveMKD

Office Phone:

EN
06/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Obalon Therapeutics

 PRESS RELEASE

Obalon Announces First Quarter 2021 Financial Results

Obalon Announces First Quarter 2021 Financial Results SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2021. On January 19, 2020 the Company signed a definitive agreement for a merger with ReShape Lifesciences Inc. Financial results for the first quarter of 2021 Revenue for the first quarter of 2021 was no...

 PRESS RELEASE

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020. On November 10, 2020, the Company signed a non-binding term sheet for merger with ReShape Lifesciences Inc. and, on January 20, 2021, announced that a definitive agreeme...

 PRESS RELEASE

Obalon Announces Third Quarter 2020 Financial Results

Obalon Announces Third Quarter 2020 Financial Results SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020. Financial results for the third quarter of 2020 Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 2019, with the decrease primarily due to the sus...

 PRESS RELEASE

Obalon Announces Consulting Agreement As Part of Strategy To Seek Cove...

Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those invo...

 PRESS RELEASE

Obalon Announces Second Quarter 2020 Financial Results

Obalon Announces Second Quarter 2020 Financial Results SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020. Financial results for the second quarter of 2020 Revenue for the second quarter of 2020 was $0.7 million, compared to $0.4 million for the second quarter of 2019, primarily due to reversals of revenue...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch